Takeda touts late-breaking Phase 3 data for TAK-921 in advanced gastric cancer at ESMO 2026

By Public Technologies
  • Takeda flagged late-breaking Phase 3 data for arcotatug tavatecan (TAK-921) for presentation at ESMO 2026 on Oct. 23.
  • The study in previously treated advanced gastric or gastroesophageal junction cancer showed outcomes that could support a Japan regulatory filing.
  • Two additional ESMO 2026 presentations will outline updated findings for TAK-928 in immunotherapy-resistant NSCLC and in first-line NSCLC.
  • A global Phase 3 trial, MarsLight-11, is enrolling to test TAK-928 against docetaxel in progressed squamous NSCLC.
  • The trial will be expanded to add a sub-study in non-squamous NSCLC, broadening the program’s commercial addressable population.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260921356638) on September 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.